Antiviral Protein-Protein Interaction Inhibitors.

Publication date: Feb 23, 2024

Continually repeating outbreaks of pathogenic viruses necessitate the construction of effective antiviral strategies. Therefore, the development of new specific antiviral drugs in a well-established and efficient manner is crucial. Taking into account the strong ability of viruses to change, therapies with diversified molecular targets must be sought. In addition to the widely explored viral enzyme inhibitor approach, inhibition of protein-protein interactions is a very valuable strategy. In this Perspective, protein-protein interaction inhibitors targeting HIV, SARS-CoV-2, HCV, Ebola, Dengue, and Chikungunya viruses are reviewed and discussed. Antibodies, peptides/peptidomimetics, and small molecules constitute three classes of compounds that have been explored, and each of them has some advantages and disadvantages for drug development.

Concepts Keywords
Construction Antiviral
Efficient Construction
Molecular Drugs
Peptidomimetics Effective
Viruses Explored
Inhibitors
Interaction
Necessitate
Outbreaks
Pathogenic
Protein
Repeating
Specific
Strategies
Viruses

Semantics

Type Source Name
disease VO Viruses
disease VO effective
disease VO efficient
disease MESH Dengue

Original Article

(Visited 1 times, 1 visits today)